Clinical trials: Natural Killer Cell Malignancies
Acute Myeloid Leukemia
QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML
This is a multi-institutional Simon's optimal two-stage phase II trial of CD3/CD19 depleted, ALT-803 activated, haploidentical donor NK cells and subcutaneous ALT-803 given after lymphodepleting chemotherapy (CY/FLU) for the…
- Trial name
- NCT03050216
- Testing
- ALT-803
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Masonic Cancer Center, University of Minnesota
Multiple Myeloma
UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma
The purpose of this study is to determine the therapeutic efficacy of the exp-NK cell therapy in research participants with relapsed high risk MM [defined as gene expression profile (GEP) 70 gene score ≥0.66 and/or metaphase…
- Trial name
- NK2010-35 (NCT01313897)
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Arkansas